Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra H Thomas

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 2, 2011
Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphomaAmrita Krishnan, Joycelynne M Palmer, Ni-Chun Tsai, et al.
Leukemia & Lymphoma|April 12, 2013
A phase I study of intravenous plerixafor following cyclophosphamide mobilization in patients with multiple myelomaAmrita Y Krishnan, Shirong Wang, Joycelynne M Palmer, et al.
Blood|May 22, 2012
Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphomaRobert Chen, Joycelynne M Palmer, Sandra H Thomas, et al.
Molecular Cancer Therapeutics|April 5, 2015
CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab VedotinRobert Chen, Jessie Hou, Edward Newman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 11, 2014
Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphomaRobert Chen, Joycelynne M Palmer, Ni-Chun Tsai, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 20, 2012
Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxisSepideh Shayani, Joycelynne Palmer, Tracey Stiller, et al.
Leukemia & Lymphoma|February 29, 2012
Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failureNitya Nathwani, Amrita Y Krishnan, Qin Huang, et al.
British Journal of Haematology|November 16, 2012
Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up studyFiroozeh Sahebi, Yan Shen, Sandra H Thomas, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 18, 2012
Second primary malignancies after autologous hematopoietic cell transplantation for multiple myelomaAmrita Y Krishnan, Matthew Mei, Can-Lan Sun, et al.
Haematologica|January 18, 2015
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphomaRobert Chen, Paul Frankel, Leslie Popplewell, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 2, 2011
Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphomaAmrita Krishnan, Joycelynne M Palmer, Ni-Chun Tsai, et al.
Leukemia & Lymphoma|April 12, 2013
A phase I study of intravenous plerixafor following cyclophosphamide mobilization in patients with multiple myelomaAmrita Y Krishnan, Shirong Wang, Joycelynne M Palmer, et al.
Blood|May 22, 2012
Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphomaRobert Chen, Joycelynne M Palmer, Sandra H Thomas, et al.
Molecular Cancer Therapeutics|April 5, 2015
CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab VedotinRobert Chen, Jessie Hou, Edward Newman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 11, 2014
Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphomaRobert Chen, Joycelynne M Palmer, Ni-Chun Tsai, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 20, 2012
Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxisSepideh Shayani, Joycelynne Palmer, Tracey Stiller, et al.
Leukemia & Lymphoma|February 29, 2012
Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failureNitya Nathwani, Amrita Y Krishnan, Qin Huang, et al.
British Journal of Haematology|November 16, 2012
Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up studyFiroozeh Sahebi, Yan Shen, Sandra H Thomas, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 18, 2012
Second primary malignancies after autologous hematopoietic cell transplantation for multiple myelomaAmrita Y Krishnan, Matthew Mei, Can-Lan Sun, et al.
Haematologica|January 18, 2015
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphomaRobert Chen, Paul Frankel, Leslie Popplewell, et al.
Pageof 4